α-Synuclein-IN-23

α-Synuclein-IN-23 (compound 2ea) (30 μM; 72 h) inhibits α-Syn aggregation with an AIR of 91.6% when incubated with 40 μM α-Syn in vitro^[1].
α-Synuclein-IN-23 (30 μM; 72 h) stabilizes the random coil conformation of α-Syn monomers and inhibits the formation of β-sheet-rich aggregates when incubated with 40 μM α-Syn in vitro^[1].
α-Synuclein-IN-23 (30 μM; 96 h) slows α-Syn fibrillation kinetics with a K_app of 0.274 h⁻¹, acting mainly by reducing oligomeric nuclei formation in the lag phase when incubated with 40 μM α-Syn in vitro^[1].
α-Synuclein-IN-23 (30 μM; 88 h) reduces the formation of large, interconnected α-Syn fibrils, resulting in shorter, sparser fibers when incubated with 40 μM α-Syn in vitro^[1].
α-Synuclein-IN-23 (30 μM; added at 21 h, 33 h, or 45 h; incubated until 88 h total) exhibits the highest disaggregation and re-aggregation inhibition activity (AIR of 87.1% at 88 h) when added at the lag phase (21 h) of α-Syn aggregation, with decreasing efficiency when added later in the process^[1].
α-Synuclein-IN-23 (10 μM; 48 h added 10 h post-transfection) inhibits α-Syn inclusion formation in △155 and SNCAIP-transfected H4 cells^[1].
α-Synuclein-IN-23 (3-10 μM; 30 min after H₂O₂ pretreatment) scavenges ROS in H4 human neuroglioma cells in a dose-dependent manner, with significant activity at 10 μM^[1].
α-Synuclein-IN-23 (1-100 μM; 48 h) exhibits low cytotoxicity in H4 and SH-SY5Y cells, with cell viability >85% at concentrations up to 100 μM after 48 h of incubation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.